Jaguar Health Signs $38 Million U.S. Licensing Deal With Future Pak for Crofelemer Products
I'm PortAI, I can summarize articles.
Jaguar Health Inc. has signed a $38 million licensing deal with Future Pak, LLC, allowing Future Pak to exclusively market Jaguar's Mytesi and Canalevia-CA1 products in the U.S. Jaguar will receive an $18 million upfront payment and up to $20 million in future milestone payments. The company will continue to manufacture the products and retains a 12-month right to reacquire product rights under certain conditions.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments